Antibody

Aβ (3D6)

Clonality: monoclonal
Host: Mouse
Methods: ELISA, IH, WB
Source: Elan Pharmaceuticals
Reactivity:
Reacts in: Human, Mouse

Immunogen/Epitope

immunogen = synthetic peptide fragment conjugated to sheep anti-mouse immunoglobulin; epitope at aa 1-5 within Aβ42

Specificity

Aβ (recognizes amino acids 1-5). Does not recognize secreted APP or APP-FL. Detects only Aβ species with amino-terminal aspartic acid.  

Note

In mouse models this antibody was shown to promote clearance and reduction of Aβ plaques. 3D6 is the parent of the humanized monoclonal antibody Bapineuzumab.

Comments / Questions

No Available Comments

Make a comment or submit a question

To make a comment you must login or register.

References

No Available References

Further Reading

Papers

  1. . CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology. 2010 Sep 21;75(12):1055-61. PubMed.
  2. . Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci. 2009 Aug 26;29(34):10706-14. PubMed.
  3. . Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12145-50. PubMed.
  4. . Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci. 2008 Jul 2;28(27):6787-93. PubMed.
  5. . Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008 Aug;14(8):837-42. PubMed.
  6. . Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008 Feb 7;451(7179):720-4. PubMed.
  7. . PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Proc Natl Acad Sci U S A. 2006 May 23;103(21):8215-20. Epub 2006 May 12 PubMed.
  8. . Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007 May 4;316(5825):750-4. PubMed.
  9. . Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Sci Rep. 2013 Feb 18;3:1302. PubMed.